Simonsen, Johan R.
Käräjämäki, Annemari
Antikainen, Anni A.
Toppila, Iiro
Ahlqvist, Emma
Prasad, Rashmi
Mansour-Aly, Dina
Harjutsalo, Valma
Järvinen, Asko
Tuomi, Tiinamaija
Groop, Leif
Forsblom, Carol
Groop, Per-Henrik
Sandholm, Niina
Lehto, Markku
Funding for this research was provided by:
Folkhälsanin Tutkimussäätiö
Finska Läkaresällskapet
Wilhelm and Else Stockmann Foundation
Vasa Hospital District
Turku University Hospital State Research Funding
Jakobstadsnejdens Heartfoundation
Medical Foundation of Vaasa
Finnish Medical Foundation
Helsingin ja Uudenmaan Sairaanhoitopiiri
Academy of Finland (275614, 299200, 316664)
Novo Nordisk Foundation (#NNF OC0013659)
Finnish Diabetes Research Foundation
Helsinki University Hospital Research Funds (EVO TYH2018207)
Article History
Received: 9 December 2020
Accepted: 23 March 2021
First Online: 4 May 2021
Competing interests
: Per-Henrik Groop has received research grants from Eli Lilly and Roche, is an advisory board member for AbbVie, Astellas, Astra Zeneca, Boehringer-Ingelheim, Eli Lilly, Janssen, Medscape, MSD, Mundipharma, Novartis, Novo Nordisk, and Sanofi. He has received lecture fees from Astellas, Astra Zeneca, Boehringer-Ingelheim, Eli Lilly, Genzyme, M.S.D., Novartis, Novo Nordisk, Peer Voice, Sanofi and SCIARC. Asko Järvinen has received lecture fees from Astellas, Biogen, MSD, OrionPharma, Pfizer and UnimedicPharma and consultation fee from CSL Behring and UnimedicPharma. Iiro Toppila is currently employed by Medaffcon Oy, Espoo, Finland. All other authors declare that there is no conflict of interest.